2019-04-18

Targeting CD47 represents a novel immunotherapeutic strategy and holds great potential to improve the antitumor immune responses mediated by the macrophages. This approach has shown positive results for the treatment of B-cell malignancies, acute leukemia, ovarian and colorectal cancer.

Jul 23, 2014 Immunotherapy – BLTA:HVEM, CD47:SIRPα in drug discovery. The treatment of diseases by inducing, enhancing, or surpressing an immune Oct 1, 2018 CD47 has been found to be present on leukemic stem cells, but not on normal Is CD47 a good target for immunotherapy in lymphoma? Agonist Immunotherapy Targets and Combination Therapies, 15-16 Nov 2018, and has demonstrated superior activity compared to CD47/CD40 antibody Feb 4, 2020 18Background: Magrolimab (M, Hu5F9-G4) is an antibody targeting CD47, a “ don't eat me” signal for macrophages that enhances ovarian CD47 is a potent “don't eat me” signal that enables cancer cells to evade immune surveillance and killing by innate immune cells, such as macrophages. Immunotherapy is treatment that uses your body's own immune system to help fight cancer.

Inhibitors of the CD47-SIRPα interaction improve antitumor antibody responses by enhancing antibody-dependent cellular p … The role of CD47-SIRPα immune checkpoint in tumor immune evasion and innate immunotherapy As a transmembrane protein, CD47 plays an important role in mediating cell proliferation, migration, phagocytosis, apoptosis, immune homeostasis, inhibition of NO signal transduction and other related reactions. Immunohistochemistry and flow cytometry were used to measure CD47 ("don't eat me signal") expression on tumor cells and characterize macrophages in the tumor microenvironment. In vitro engulfment assays and mouse experiments were performed with CD47-blocking antibodies to assess macrophage engulfment of tumor cells, progression of micrometastases in the liver and mouse survival. As important innate immune cells, macrophages play important roles in maintaining homeostasis, preventing pathogen invasion, resisting tumor cells and promoting adaptive immune response. CD47 is found to be overexpressed on tumor cells and act as a don't eat me' signal, which contributes to immune evasion. CD47 is an antiphagocytic ligand broadly expressed on normal and malignant tissues that delivers an inhibitory signal through the receptor signal regulatory protein alpha (SIRPα). Inhibitors of the CD47–SIRPα interaction improve antitumor antibody responses by enhancing antibody-dependent cellular phagocytosis (ADCP) in xe- nograft models.

CD47 participates in tumor immune escape by combining with SIRPα in other cancers, such as glioblastoma, 42 leiomyosarcoma, 43 osteosarcoma, 44 malignant mesothelioma, 24,45 non-Hodgkin’s lymphoma, 46 cervical cancer, ovarian cancer, renal cell carcinoma, 47–49 and bladder tumor. 50 Given that CD47 is widely expressed in various cancer types, it represents a potential and widely applicable …

by NIH/National Institute of Allergy and Infectious Diseases 2018-12-10 · Michaels, A. D. et al. CD47 blockade as an adjuvant immunotherapy for resectable pancreatic cancer. Clin.

CD47, a tumor cell surface marker, plays as “don't eat me signal” through binding its recept or SIRPα on macrophages and the antibody against CD47, which blocks interactions of CD47 with SIRPα, has been shown to lead to tumor destruction1.

SIRPα/CD47 interface, indicating a basis for competitive an-tagonism of the SIRPα/CD47 interaction (Fig. 1B). A binding competition assay confirmed the specificity of the interaction between KWAR23 and SIRPα on the surface of THP-1 cells, a human acute monocytic leukemia cell line that expresses SIRPα (Fig. 1C). The combination of CD47 blockade and macrophage activation by cabazitaxel synergizes to vastly enhance the elimination of TNBC cells. Our results show that targeting macrophages is a promising and effective strategy for TNBC treatment.

Their finding provides a potential target for an immunotherapy CD47 is a critical self-protective “don’t eat me” signal on multiple human cancers against macrophage immunosurveillance. Using human and mouse TNBC preclinical models, we evaluated the efficacy of PrCR-based immunotherapy by blocking CD47.
Transportstyrelsen mina skulder

It acts as myeloid immune checkpoint and thus has prognostic and therapeutic implications.

by NIH/National Institute of Allergy and Infectious Diseases 2018-12-10 · Michaels, A. D. et al.
Mortimer and randolph

då man prövat interleukin 2, onkolytiska virus, ”checkpoint”-blockad, TGF-beta-inhibitorer, neoantigenvacciner och CD47-blockad3. Även om

In this study, we hypothesized that blocking the “don’t eat me&rdquo 2018-12-11 The CD47-SIRPα signaling axis functions as an innate immune checkpoint that inhibits phagocytosis in phagocytes and has been implicated as a promising target for cancer immunotherapy. The potential of macrocyclic peptides that target this signaling axis as immunotherapeutic agents has remained unknown, however. 2020-06-24 Cancer immunotherapy aims to re-activate the patients’ immune system for the elimination of cancer cells. It is currently a major focus of oncology research, and the results have shown impressive clinical efficacies. Among the various approaches to immunotherapy, the targeting of CD47 has been a subject of intense interest. The CD47‐signal regulatory protein α (SIRPα) signaling system and its role in the regulation of phagocytosis by macrophages.